TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07697560: Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

Sponsor: AnHorn Medicines Co. Ltd. · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT07697560 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07697560 Rescue Dossier →